×
About 180,230 results

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Sep 28th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

Quadratus Lumborum Type 2 as Chronic Hip Pain Treatment
https://clinicaltrials.gov/ct2/show/NCT04438265

Sep 30th, 2022 - The lumbar square block is an interfascial block of the posterior wall of the abdomen, initially described for the management of postoperative pain in abdominal surgery due to its suggested effect on the T7-11 roots. The analgesic efficacy of type 1 lumbar square block (QL1) in hip surgery was subsequently published. Regarding chronic pain, QL2 has been successfully performed in posttherniorrha...

Exercise Capacity Under Various FiO2 and Oxygen Flow Rates Using HFNC
https://clinicaltrials.gov/ct2/show/NCT04471220

Sep 30th, 2022 - In the pervious study, the investigators demonstrated that 4 weeks of training using both high FIO2 and high flow through an HFNC significantly improved the 6MWD compared with training using a 6 L/min nasal cannula. However, it was unclear whether the effects of pulmonary rehabilitation under HFNC were due to high FIO2, high flow rate, or a synergistic effect. It is also unknown whether there a...

Biomarkers in Ocular Inflammation and Uveitis
https://clinicaltrials.gov/ct2/show/NCT04690829

Sep 30th, 2022 - Uveitis refers to a large group of intraocular inflammatory diseases that can cause devastating visual loss in adults and children. This is a retrospective study to identify factors and biomarkers that are relevant to the pathogenesis, progression, and treatment response in inflammatory eye conditions. The primary objective is to identify ocular imaging, clinical and laboratory biomarkers in or...

Time-restricted Eating in Morning Chronotype
https://clinicaltrials.gov/ct2/show/NCT04618133

Sep 30th, 2022 - Overweight and obesity are highly prevalent conditions worldwide, despite active research of new interventions over decades. Current interventions include medications or bariatric surgery, but these approaches cannot be used in all patients and require clear indications and a close multidisciplinary management. Therefore most patients and physicians rely on lifestyle interventions, focusing on ...

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
https://clinicaltrials.gov/ct2/show/NCT04718181

Sep 30th, 2022 - Part 1 of the study is an exploratory comparison of the relative oral bioavailability of the two dispersible tablets versus risdiplam powder for oral solution as the reference. The effect of food on the bioavailability of the two dispersible tablets will be assessed by comparing fed and fasted states in a five-way crossover manner. It will also be assessed whether antacids (omeprazole) have an ...

Data Collection Study of Pediatric and Adolescent Gynecology Conditions
https://clinicaltrials.gov/ct2/show/NCT04717349

Sep 30th, 2022 - Study Description: The overall purpose of PAG evaluations under this protocol is to gather information over time from a large group of patients with PAG conditions to help improve our understanding of these conditions. Our aim is to create a large database of PAG conditions in presentation and variety. Objectives: Primary Objective: Recruit a diverse population of pediatric and adult subjects w...

Schulze Muscular Dystrophy Ability Clinical Study
https://clinicaltrials.gov/ct2/show/NCT05409079

Sep 30th, 2022 - The primary objective of the Schulze study is to evaluate the function of the upper limbs of subjects diagnosed with neuromuscular disorders, with and without use of the Abilitech Assist device in the clinic and home environments. Functional outcomes will include documenting active range of motion and the ability to perform activities of daily living (ADLs) using the standardized Canadian Occup...

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
https://clinicaltrials.gov/ct2/show/NCT05407584

Sep 30th, 2022 - This study is a single arm phase II study in patients with PARP inhibitor-resistant ovarian cancer. The efficacy and safety of five administrations of Oregovomab 2mg IV in combination with PLD and Paclitaxel will be evaluated with recurrent ovarian cancer who have progressed with prior PARP inhibitor treatment. A total of 56 subjected will be enrolled in this study from 4 sites in South Korea. ...

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT05286814

Sep 30th, 2022 - Background: Regional chemotherapy for hepatic malignancies takes advantage of the fact that tumors are perfused almost exclusively by the hepatic artery and, that the agent used (Floxuridine, FUDR) has a 95% first-pass metabolism by the liver. Early clinical trials performed during the 1970's and 1980's demonstrated impressive response rates that led to the adoption of hepatic artery infusion p...

Rare Tumors and Cancer Predisposition in Individuals and Families
https://clinicaltrials.gov/ct2/show/NCT05350761

Sep 30th, 2022 - Study Description: The overall purpose of this study is to comprehensively and longitudinally evaluate the natural history of participants with rare tumors, genetic syndromes, genetic variants, and/or family history consistent with or hypothesized to contribute to predisposition to cancer(s) of interest to DCEG investigators. It will also facilitate evaluation of patients who may be candidates ...

NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
https://clinicaltrials.gov/ct2/show/NCT05375812

Sep 30th, 2022 - Study Description: This protocol is part of a joint collaboration with the Veterans Administration (VA) known as (Project IN-DEPTH). The Veterans Administration protocol will recruit and identify participants for the NIH study, and maintain a repository of samples through a VA protocol (VA IN-DEPTH). The NIH protocol (NIH IN-DEPTH) will conduct deep phenotyping evaluations on study participants...

EFFects of EXPosure and Cognitive-behavioural Therapy for Chronic BACK Pain
https://clinicaltrials.gov/ct2/show/NCT05294081

Sep 30th, 2022 - According to a recently published study by the Robert Koch Institute with over 62 000 participants, one in six men (17.1%) and one in four women (24.4%) in Germany reported having suffered from chronic low back pain (CLBP) in the last 12 months. CLBP is a major cause of medical costs, absenteeism and disability. Despite apparent advances in medical care, the prevalence of CLBP continues to rise...

Ketorolac in Hand and Wrist Tendinopathy and Arthropathy
https://clinicaltrials.gov/ct2/show/NCT05292339

Sep 30th, 2022 - Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the hand and wrist are common yet disabling diseases. These pathologic processes are progressive and painful leading to significant impairments on quality of life. Diagnosed patients experience a profound reduction of strength and dexterity hindering all activities of daily living. For a majority of the aforementioned ...

Evaluation of Children With Endocrine and Metabolic-Related Conditions
https://clinicaltrials.gov/ct2/show/NCT02769975

Sep 30th, 2022 - Study Description: This protocol is designed to allow endocrine-related evaluations of children with known or suspected endocrine or metabolic disorders. Children with endocrine or metabolic-related condition(s) who may or may not be eligible for a specific NICHD research protocol, may be evaluated under the auspices of this protocol. Standard clinically indicated laboratory or radiological stu...

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
https://clinicaltrials.gov/ct2/show/NCT04535414

Sep 30th, 2022 - Background: Hereditary Diffuse Gastric Cancer (HDGC) is most often attributed to inactivating germline mutations in the E-cadherin (CDH1) tumor suppressor gene. Mutation carriers have a 24-70% lifetime risk of developing gastric adenocarcinoma. International consensus guidelines recommend endoscopic screening and surveillance of CDH1 mutation carriers who decline risk-reducing total gastrectomy...

Virtually Augmented Self Hypnosis in Peripheral Vascular Interventions
https://clinicaltrials.gov/ct2/show/NCT04561596

Sep 30th, 2022 - The participants in the control group will be treated under local anesthesia, following the usual care protocols. The participants in the experimental group will be treated under the same conditions, except that they will experience virtual reality autohypnosis during the intervention.

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04222413

Sep 30th, 2022 - Background: Metarrestin is a first-in-class investigational agent targeting the peri-nucleolar compartment (PNC), a marker of genome organization associated with metastasis. Preclinical studies have shown that metarrestin effectively suppresses metastasis and extends overall survival in different cancer models. Multi-species allometric scaling and good laboratory practice (GLP) toxicology and t...

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT04239027

Sep 30th, 2022 - Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss. The safety and efficacy of brolucizumab has been demonstrated in 2 ran...

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
https://clinicaltrials.gov/ct2/show/NCT04099966

Sep 30th, 2022 - Patients wiith selected malignant or non-malignant conditions meeting eligibility criteria will be enrolled on this study. Patients will receive one of either full intensity, reduced intensity, or reduced toxicity conditioning appropriate based on disease, disease status, organ function and performance status and will undergo α/β T-cell and CD 19+ B cell depleted alloSCT. Patients will be follo...